In endometrial cancer, it was reported to be downregulated and to modulate the expression of members of the AKT pathway and inhibit cell proliferation (Cai et al., 2018; Visvanathan et al., 2018; Miao et al., 2019; Peng et al., 2019; Li et al., 2020; Liang et al., 2020; Nombela et al., 2021). This evidence concerns the gene AKT1 and endometrial cancer.